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Background: Although cells require nutrients to proliferate, most nutrient exchange rates of the NCI60 panel of
cancer cell lines correlate poorly with their proliferation rate. Here, we provide evidence indicating that this
inconsistency is rooted in the variability of cell size.
Results: We integrate previously reported data characterizing genome copy number variations, gene expression,
protein expression and exchange fluxes with our own measurements of cell size and protein content in the NCI60
panel of cell lines. We show that protein content, DNA content, and protein synthesis per cell are proportional to
the cell volume, and that larger cells proliferate slower than smaller cells. We estimate the metabolic fluxes of these
cell lines and show that their magnitudes are proportional to their protein synthesis rate and, after correcting for
cell volume, to their proliferation rate. At the level of gene expression, we observe that genes expressed at higher
levels in smaller cells are enriched for genes involved in cell cycle, while genes expressed at higher levels in large
cells are enriched for genes expressed in mesenchymal cells. The latter finding is further corroborated by the
induction of those same genes following treatment with TGFβ, and the high vimentin but low E-cadherin protein
levels in the larger cells. We also find that aromatase inhibitors, statins and mTOR inhibitors preferentially inhibit the
in vitro growth of cancer cells with high protein synthesis rates per cell.
Conclusions: The NCI60 cell lines display various metabolic activities, and the type of metabolic activity that they
possess correlates with their cell volume and protein content. In addition to cell proliferation, cell volume and/or
biomarkers of protein synthesis may predict response to drugs targeting cancer metabolism.
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Cancer cells exhibit metabolic phenotypes that distin-
guish them from normal tissue cells, in particular an in-
creased activity of metabolic pathways necessary for cell
growth [1,2]. In turn, accumulating evidence indicates
that major oncogenes, for example, Ras and Myc, posi-
tively regulate metabolic pathways that are upregulated
in cancer cells [2-6], whereas tumor suppressors like p53
negatively regulate them [7,8]. However, a parallel un-
derstanding of cancer metabolism from basic principles
is also needed, particularly in cases where the regulatory* Correspondence: alexei.vazquez@rutgers.edu
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reproduction in any medium, provided the ormechanisms contradict what is expected from efficiency.
A good example is the Warburg effect [9]: the observa-
tion of a high glycolysis rate under normal oxygen
conditions (aerobic glycolysis). While we have some un-
derstanding of the regulatory mechanisms activating gly-
colysis, it is not clear why the less efficient glycolysis
(two ATP molecules per glucose molecule) is preferred
to the more efficient oxidative phosphorylation (oxida-
tive phosphorylation (OxPhos), 32 ATP molecules per
glucose molecule).
The yield of ATP per glucose molecule has generally
been used to compare the efficiency of glycolysis and
OxPhos. However, cell metabolism can also be con-
strained by the solvent capacity of the cell cytoplasm,
that is, the maximum amount of macromolecules that
can occupy the intracellular space [10,11]. The simultan-
eous consideration of glucose uptake and solventd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effect [1]: at low glucose uptake rates when the glucose
uptake capacity is the limiting factor, mitochondrial
respiration is indeed the most efficient pathway for
ATP generation. Above a threshold glucose uptake rate,
however, the solvent capacity becomes the limiting factor,
resulting in gradual activation of aerobic glycolysis and
slight decrease of mitochondrial respiration. Therefore the
Warburg effect is a favorable catabolic state for all rapidly
proliferating mammalian cells with high glucose uptake
capacity. Although aerobic glycolysis is less efficient
than mitochondrial respiration in terms of ATP yield
per glucose uptake, it is more efficient in terms of the
required solvent capacity [1].
Our understanding of the amino-acid demand of cancer
cells remains incomplete as well. It has been recently
shown that the exchange rates of most nutrients correlate
poorly with their proliferation rate in 60 tumor-derived
cell lines (NCI60) growing in standard culture conditions
[12]. These cell lines have been utilized by the National
Cancer Institute (NCI) to screen for anticancer drugs [13]
and the understanding of their metabolism may aid in the
identification of small molecules targeting cancer metab-
olism. Here we investigate the origin of this apparent in-
consistency between metabolite exchange fluxes and cell
proliferation, taking into account the variability of cell size
and protein content among the NCI60 cell lines. We use
these insights to reassess the NCI drug screening data,
allowing us to start to personalize drug therapies targeting
cancer metabolism.
Methods
Cell-doubling times
The doubling times were obtained from the Developmental
Therapeutics Program of the NCI (http://dtp.nci.nih.gov/
docs/misc/common_files/cell_list.html), and have been con-
firmed for a subset of cell lines [12].
Protein synthesis rate estimation
The protein synthesis rate was estimated from the ex-
change fluxes of essential amino acids, as described in
Additional file 1.
Protein synthesis rate validation
Log-phase cells seeded in 6-well plates the previous
day were incubated with pre-warmed RPMI 1640
medium containing 2 μCi/mL (4,5-3H)-leucine (Moravek
Biochemicals and Radiochemicals, Brea, CA, USA) at 37°C.
At predetermined time points (5, 15 and 30 minutes),
monolayers were washed twice with ice cold PBS and
0.5 ml of ice cold 10% perchloric acid was added to each
well. After 20 minutes incubation, the plates were
scraped into a microcentrifuge tube and the samples
were centrifuged at 15,000 × g for 10 minutes. The pelletwas washed with 10% perchloric acid, centrifuged again and
then solubilized with 0.2 M NaOH. The sample was added
to a scintillation tube containing 2.5 mL of Ultima-Gold
liquid scintillation cocktail (Perkin-Elmer, Waltham, MA,
USA), vortexed until the solution was clear and 3H counts
per minute (CPM) were determined using an LS6000SC
Beckman Coulter liquid scintillation counter. At each time
point CPMs were normalized by the cell number count:
(4,5-3H)-leucine incorporation rate was determined as
the slope of the plot of CPM/cell as a function of time
(Additional file 1: Figure S1).
Cell size measurements
Cells were grown in RPMI 1640 medium containing 5%
FBS and 2 mM L-glutamine at 37°C and 5% CO2, as
described previously. Each cell sample was pipetted
into the disposable counting chamber and bright-field
images were captured for image analysis in duplicate.
Cell diameter was measured with the Cellometer Auto T4
(Nexcelom Bioscience LLC, Lawrence, MA, USA). This
image cytometer utilizes a bright-field (BR) light micros-
copy optical setup for image cytometric analysis [14]. The
combination of microscope objective (4×) and digital
camera provides resolution of approximately 1.05 μm2/pixel,
which is utilized to calculate accurate cell size of the target
sample. The system has a motorized assembly that automat-
ically acquires bright-field images of the target sample. The
disposable counting chamber holds precisely 20 μL of the
cell sample. Two separate areas are imaged and analyzed on
the imaging platform, where the target cells are identified
and counted by the Cellometer software. The cell volume
was estimated assuming a spherical shape. The validity of
the latter assumption is supported by the reported linear
relationship between the estimated cell volume and the
measured protein content, a surrogate of cell size. The cell
size data will be available on the Nexcelom Biosciences
website (http://www.nexcelom.com).
Protein content measurements
NCI60 cell lines were grown in complete medium
containing RPMI 1640, with 2 mM L-glutamine and 5%
FBS. Cells were seeded in triplicate wells in 6-well plates
and maintained at 37°C, 5% CO2 until reaching 70 to 80%
confluency. Cells were then trypsinized and collected for
cell count and total protein extraction. Cell number was
determined using the Vi-CELL Cell Viability Analyzer
(Beckman Coulter, Indianapolis, IN, USA). The remaining
cells from each well were centrifuged at 1500 g for 5 min
and washed with 1X PBS. Cell lysates were prepared in
radioimmunoprecipitation assay (RIPA) buffer with 1%
protease inhibitor cocktail. Protein concentration was
determined by Bradford assay (Bio-Rad, Hercules, CA,
USA). Protein content/cell was calculated based on total
protein content/well and total cell number/well.
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The DNA content was estimated from previously re-
ported karyotypes for the NCI60 cell lines [15] and
the chromosome sizes reported by Ensembl. DNA
content inferred from copy number profiles is in close
correspondence with DNA content measured by flow
cytometry [16].
Statistical test for volume dependence
Given a test quantity Yi (protein content, DNA content
or protein synthesis rate) measured across i = 1,…,n cell
lines with cell volumes Vi, we assume that:
Y i ¼ μV αi þ σV βi Xi
where μ and σ are model parameters and α = β = 0 for the
volume independent (I) model, α = 1 and β = 0 for the vol-
ume dependent mean (VDM), and α = β = 1 for the vol-
ume dependent mean and variance (VDMV) model, and
Xi are independent random variables with a standard nor-
mal distribution. For each model, we assign to μ and σ
their maximum likelihood estimates (Additional file 1).
The validity of each model is then quantified applying the
Shapiro-Wilk normality test to:
Xi ¼ Y i−μV αi
 
=σV β=2i
A model is rejected if the resulting statistical signifi-
cance falls below 0.05.
Personalized metabolic models
Personalized metabolic models are described in Additional
file 1.
Gene expression profiles
Affymetrix HG-U133 Plus 2.0 gene expression arrays for
the NCI60 cell lines were reported previously [17] and these
were downloaded from CellMiner, (http://discover.nci.nih.
gov/cellminer/loadDownload.do), GCRMA normalization.
Log2 expression values were used for analysis.
Protein expression profiles
The expression of 194 proteins and phosphoproteins in
the NCI60 cell lines was previously reported [18] and
these were downloaded from CellMiner, (http://discover.
nci.nih.gov/cellminer/loadDownload.do) Log2 protein ex-
pression values were used for analysis.
Gene ontology (GO) analysis
Given the list of genes associated with a GO term, a
hypergeometric test was performed to determine the
significant enrichment of those genes within the list
of genes with at least one Affymetrix HG-U133 Plus
2.0 probe that is positively (negatively) correlated with
cell volume.Correlation analysis
All reported correlations between metabolic fluxes and
cell variables were quantified using the Pearson correl-
ation coefficient (PCC). The statistical significance of the
observed PCC was estimated using a permutation test.
The statistical significance P was computed as the frac-
tion of times the PCC of the permuted variables was as
large as, or larger than the observed value in 108 such
permutations.
Results
The exchange of essential amino acids is proportional to
their abundance in the proteome
Proteins make up about 70% of cell dry weight. This
high protein-content is associated with high metabolic
demand for protein synthesis, to balance the basal pro-
tein turnover and sustain cell growth [2]. A component
of this metabolic demand is the import of essential
amino acids (that is, amino acids that cannot be synthe-
sized by human cells) for subsequent protein synthesis.
We hypothesized that the import rate of an essential
amino acid is proportional to the protein synthesis rate,
with a coefficient of proportionality matching its relative
abundance in the proteome (Additional file 1: Table S1).
The validity of this assumption was tested using the
measured metabolic exchange fluxes reported for the
NCI60 panel of tumor-derived cell lines [12]. Plotting of
the import rate of one essential amino acid versus an-
other produces an evident linear relationship between
the two (Figure 1a, symbols). More importantly, the
slope matches the ratio of their relative abundance in
the human proteome (Figure 1a, red line). Exploiting
this relationship, we obtained a maximum likelihood
estimate (MLE) of the protein synthesis rate for each
cell line in the NCI60 panel. A posteriori, we plotted
the import rate of essential amino acids as a function of
the MLE protein synthesis rate, corroborating their
proportionality (Additional file 1: Figure S1). To valid-
ate the MLE protein synthesis rate we quantified the
protein synthesis rates of selected cell lines by measur-
ing the rate of (4,5-3H)-leucine incorporation into pro-
tein. The measurements obtained from both methods
are proportional to each other (PCC = 0.99) (Additional
file 1: Figure S2).
The overall exchange of serine and glycine matches the
requirements of protein synthesis
Next, we investigated the exchange rate of the non-
essential amino acids, serine and glycine, in relation to
the estimated protein synthesis rates. Serine was
imported from the growth medium in all the reported
cancer cell lines, at a magnitude that is proportional
but higher than the expected serine demand for protein
synthesis (Figure 1b). In contrast, glycine was either
Figure 1 Import rate of amino acids. Each square symbol represents a cell line, the red solid lines indicate the expected amount given the
demand of protein synthesis and the dashed red lines are linear fits to the data points. (a) Valine versus leucine import rate. (b) The import rate
of serine as a function of the maximum likelihood estimate (MLE) protein synthesis rate. (c) The import rate of glycine as a function of the MLE
protein synthesis rate. The cell lines below the blue dashed-dotted line export glycine. (d) The sum of serine and glycine exchange rates results
in a net import that matches the overall serine and glycine requirements for protein synthesis. (e) Putative rate of serine to glycine conversion
(catalyzed by serine hydroxymethyl transferase), calculated as the expected glycine supply for protein synthesis minus the observed glycine
exchange. (f) Lactate excretion as a function of the glucose uptake rate. (g) Lactate excretion as a function of the MLE protein synthesis rate. The
red line represents the ATP demand of protein synthesis (4.27 ATP/amino acid [19]). (h) Glycine exchange rate as a function of the proliferation
rate. (i) Glycine exchange rate as a function of the DNA synthesis rate.
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medium) at a magnitude that was proportional, but lower
than the expected glycine demand for protein synthesis
(Figure 1c). Interestingly, when both contributions are
added up, the overall serine + glycine exchange matches
what is required for protein synthesis in all NCI60 cell
lines (Figure 1d). These data indicate that to a variable ex-
tent, in all cancer cells there is a putative net conversion
of serine to glycine, catalyzed either by the cytosolic or
mitochondrial serine hydroxymethyl transferase (SHMT1
and SHMT2, respectively). Furthermore, the net putativeSHMTactivity was approximately proportional to the pro-
tein synthesis rate (Figure 1e). However, since serine and
glycine participate in metabolic pathways other than pro-
tein synthesis, we cannot establish a causal link between
the protein synthesis rate and the overall exchange rate of
serine and glycine.
The rate of aerobic glycolysis is consistent with the ATP
demand of protein synthesis
Protein synthesis is an energy-demanding biosynthetic
process. As most cancer cells have a high rate of glycolysis,
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by Jain et al. [12], we also found that a significant fraction
of glucose (approximately 70%) was converted to lactate in
proportion to the glucose uptake rate (aerobic glycolysis,
Figure 1f). Assuming that most of the excreted lactate is
formed from glucose and that most of the lactate pro-
duced from glucose is excreted, the lactate excretion rate
is a surrogate for ATP production from aerobic glycolysis.
Surprisingly, the lactate excretion rates were approxi-
mately proportional to the protein synthesis rates in a ra-
tio close to the energy demands of protein synthesis
(Figure 1g). This scaling relationship indicates that the
amount of ATP generated by aerobic glycolysis is approxi-
mately equal to the energy requirements for protein syn-
thesis in cancer cells.
The correlation between protein synthesis and aerobic
glycolysis rates is supported by previous investigations of
protein translation and the mTOR pathway, which plays
a major role in its regulation. Treatment with translation
initiation inhibitors decreases the glucose uptake and
the lactate excretion of cancer cell lines grown in vitro
[20]. mTORC1 activation increases glucose uptake,
whereas treatment with the mTOR inhibitor, rapamycin,
decreases glucose uptake [21]. However, further experi-
ments are required to establish a causal link between the
energy demands of protein synthesis and the rate of
aerobic glycolysis.
Glycine exchange is correlated with proliferation and DNA
synthesis rates
As previously noted by Jain et al. [12], we corrobo-
rated that the glycine exchange rate is significantly
correlated with the proliferation rate of the NCI60 cell
lines (PCC= 0.51, P= 7 × 10-6) (Figure 1h). Furthermore,
experiments with 13C-labelled glycine demonstrated the
incorporation of glycine carbons into purine nucleotides
[12]. However, the relationship between glycine exchange
and DNA synthesis rates has not been determined. Using
the reported karyotypes for the NCI60 cell lines [15], we
estimated the DNA content of each cell line. Next we
estimated the DNA synthesis rate by multiplying the
DNA content by the proliferation rate. We found that
the glycine exchange rate was significantly correlated
with the DNA synthesis rate (PCC = 0.37, P = 0.0026)
(Figure 1i).
The protein synthesis rates are proportional to the cell
volumes
The estimated protein synthesis rates for the NCI60
panel of cancer cell lines were not significantly corre-
lated with their proliferation rate (PCC = 0.088, P = 0.25)
(Additional file 1: Figure S3). Given that the reported ex-
change fluxes were reported per cell number, we hypoth-
esized that variations in cell size may be responsible forthe lack of correlation. To gain further insight into this
issue, we measured cell size and protein content of each
cell line in the NCI60 panel, and estimated the cell vol-
ume assuming a spherical shape. The estimated cell line
volumes are distributed between 1 and 4 pL. Examples
of both extremes are shown in Figure 2a and b. There
was a positive correlation between cell volumes and the
reported doubling times (PCC = 0.45, P = 0.00027), in-
dicating that, on average, slowly dividing cells tended
to be larger (Figure 2c). Similarly, the protein content
per cell was positively correlated with cell doubling
time (PCC = 0.38, P = 0.0026). However, the estimated
DNA content of the NCI60 cell lines did not significantly
correlate with their proliferation rate (PCC = 0.17, P =
0.092). As anticipated by the correlation of both the pro-
tein content and cell volume with the doubling time, we
observed positive correlation between the protein content
and the cell volume (PCC= 0.69 P <10-6), with a typical
protein concentration of 0.14 g/mL (Figure 2d). The DNA
content was also positively correlated with the cell volume
(PCC = 0.51, P = 0.000032) (Figure 2e) and with the
protein synthesis rate (PCC = 0.43, P = 0.00078). Finally,
the protein synthesis rate per cell was also positively
correlated with the cell volume (PCC = 0.55, P = 0.000011)
(Figure 2f), with a typical rate of 38.1 mmol/L/h.
From Figure 2d we observe that the spread of the pro-
tein content around the dashed red line increases with
increasing the cell volume. This observation suggests
that not only the average but also the variance of the
protein content may be a function of the cell volume.
The same trend is evident both for the DNA content
(Figure 2e) and the protein synthesis rate (Figure 2f ).
To account for this possibility, we tested three different
models representing the dependence of each quantity
with the cell volume. The first model assumes that the
tested quantity (protein content, DNA content or pro-
tein synthesis) is independent of the cell volume, inde-
pendent (I). The second model assumes that the
expected value of the tested quantity increases with the
cell volume but the variance is independent of the cell
volume, volume dependent mean (VDM). The third
model assumes that both the expected value and the
variance of the tested quantity increase with the cell vol-
ume, volume dependent mean and variance (VDMV).
For the three quantities we can rule out the independent
model (protein content, pI = 0.0039; DNA content, pI =
0.0077; protein synthesis, pI = 0.00028). In the case of
the protein content, we could not reject the VDM model
(pVDM = 0.55), neither the VDMV model (pVDVM = 0.93),
although the VDMV seems more likely (pVDVM = 0.93 vs
pVDM = 0.55). In the case of the DNA content, we can
rule out the VDM model (pVDM = 0.0057) whereas the
VDMV model is a good representation of the data
(pVDMV = 0.83). In contrast, for the protein synthesis rate
Figure 2 Correlation between biomass components and doubling time or cell size. (a) Culture image of the relatively smaller colon cancer
cell line HCT-116. (b) Culture image of the relatively larger renal cancer cell line A498. (c) The cell volume scales in proportion with the doubling
time. The diamond and circle represent the HCT-116 and A498 cell lines, respectively. (d-f) The protein content, DNA content and protein synthesis
rate scale in proportion to the cell volume. The blue dashed-dotted line in panel (e) represents the DNA content associated with the diploid genome
of a normal cell. All other lines represent linear fits to the data points.
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while the VDM model is a good representation of the
data (pVDM = 0.57). Taken together, these statistical ana-
lyses indicate that the average and the standard deviation
of the protein and DNA content across cell lines in-
creases proportionally to the cell volumes. The average
protein synthesis rate across cell lines also increases with
the cell volumes, but with a standard deviation that is
independent of the cell volume.
Association between protein synthesis rates and internal
metabolic fluxes
To further understand the impact of cell size and pro-
tein synthesis rates on cell metabolism, we developed
personalized metabolic models for each cell line in the
NCI60 panel, by taking into account their measured cell
volume, estimated DNA content and previously reported
exchange fluxes. However, we did not constrain the
model by the protein content of each cell line. As dis-
cussed above, the rate of protein synthesis and the asso-
ciated protein content can be deduced from the
exchange fluxes of essential amino acids. In this way, the
comparison of the model-predicted protein content and
the measured values may be used as an independentvalidation. The model-predicted protein synthesis rates
are highly correlated with the MLE values (PCC = 0.97,
P <10-6) (Additional file 1: Figure S4a). As theoretically
expected, the model predicts slightly lower values. The
MLE predicts a protein synthesis rate that is a consensus
between the observed essential amino acids import rates.
Instead, the metabolic model predicts the protein syn-
thesis rate that is consistent with the limiting essential
amino acid, that is, the essential amino acid whose ex-
change rate results in the lowest protein synthesis rate
when assuming that all other essential amino acids can
be imported at any rate. The model predicted protein
content is also significantly correlated with the measured
protein content (PCC = 0.49, P = 0.00039) (Additional
file 1: Figure S4b). We note that the agreement is not
perfect. The differences could be attributed in part to
the lack of cell line-specific measurements of the basal
protein degradation rate, among other factors. Neverthe-
less, the model captures the right trend and it can be
used to investigate the correlation between internal
fluxes and the proliferation or protein synthesis rate.
The model-predicted metabolic fluxes can be roughly
divided in three major categories based on their magni-
tude. Glycolysis is in the first category, with rates as high
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synthase catalyzed flux rate in that range (Figure 3c),
indicating that OxPhos in the mitochondria contributes
to energy generation in an amount comparable to
that by glycolysis. Glutaminolysis is in a second cate-
gory, with intermediate rates around 1/10 pmol/cell/h
(Figure 3d). Overall, the imported glutamine is utilized
as a precursor amino acid in protein synthesis and con-
verted to glutamate. The produced glutamate is also uti-
lized as a precursor amino acid in protein synthesis,
converted to α-ketoglutarate by different transaminases in
the cytosol and the mitochondria (Figure 3e), and excreted
(Figure 3f). Among the transaminases, phosphoserineFigure 3 Metabolic flux distribution as a function of the protein synth
rates of the reaction indicated in the y-axis as a function of the maximum
cell lines. Panels with no error bars represent exchange fluxes that were us
estimates using our personalized metabolic models. In the latter, each
explored (Additional file 1) and the error bars represent the 90% CI. The dashetransaminase (PSAT) links serine synthesis from 3-
phosphoglycerate to glutaminolysis (Figure 3g), as previ-
ously reported for breast cancer and melanoma cell
lines [22,23]. Finally, the third category comprises reac-
tions with fluxes in the range of 1/100 pmol/cell/h, includ-
ing the oxidative branch of the pentose phosphate pathway
(PPPox, Figure 3h), and the reactions catalyzed by pyru-
vate dehydrogenase (PDH, Figure 3i) and pyruvate carb-
oxylase (PC, Figure 3j). The rate of all these reactions is
significantly correlated with the protein synthesis rate, as
can be observed from direct inspection of the panels in
Figure 3, and as quantified in Table 1, with the notable ex-
ceptions of aspartate and glycine exchange rates.esis rate. (a-j) Selected metabolic pathways are shown. Shown are
likelihood estimate (MLE) protein synthesis rate (x-axis) for the NCI60
ed as input to the model. Panels with error bars represent flux
point represents the median over the range of kinetic parameters
d lines are linear fits through the origin.
Table 1 Correlation of exchange fluxes with proliferation rate and protein synthesis rate
Flux per cell versus
proliferation rate
Flux per cell versus protein
synthesis rate
Flux per cell volume versus
proliferation rate
PCC P PCC P PCC P
Protein synthesis 0.09 0.250214 1.00 0.000000 0.55 0.000004
Essential amino acids Isoleucine 0.05 0.349331 0.96 0.000000 0.48 0.000082
Leucine 0.08 0.281351 0.98 0.000000 0.54 0.000008
Lysine 0.16 0.108393 0.95 0.000000 0.56 0.000003
Methionine 0.20 0.065968 0.92 0.000000 0.65 0.000000
Phenylalanine 0.12 0.184280 0.97 0.000000 0.59 0.000001
Threonine −0.01 0.466997 0.92 0.000000 0.42 0.000519
Tryptophan 0.01 0.459913 0.83 0.000000 0.37 0.002299
Valine 0.06 0.333105 0.97 0.000000 0.49 0.000068
Non-essential amino acids Alanine 0.38 0.000912 −0.55 0.000040 0.11 0.200642
Arginine 0.10 0.230809 0.45 0.001921 0.39 0.001534
Asparagine 0.15 0.134489 0.51 0.000448 0.43 0.000407
Aspartate 0.04 0.373865 0.18 0.081690 0.14 0.151826
Glutamine −0.23 0.032499 0.78 0.000000 0.13 0.156961
Glutamate 0.26 0.018120 −0.59 0.000080 0.14 0.137636
Glycine 0.51 0.000007 −0.12 0.179629 0.47 0.000066
Proline 0.21 0.047898 −0.30 0.014511 0.03 0.398548
Serine −0.10 0.226831 0.83 0.000000 0.29 0.012954
Tyrosine 0.07 0.282791 0.96 0.000000 0.52 0.000014
Other Glucose −0.17 0.092456 0.80 0.000000 0.21 0.058257
Lactate 0.22 0.043187 −0.76 0.000000 −0.13 0.157716
PPPox 0.34 0.004365 0.66 0.000000 1.00 0.000000
PSAT −0.16 0.104559 0.73 0.000000 0.24 0.033800
PDH 0.48 0.000078 0.29 0.018433 0.72 0.000000
PC 0.02 0.445333 0.52 0.000207 0.35 0.003715
Glutamate→α-KG 0.05 0.358935 0.80 0.000000 0.64 0.000000
ATP synthase 0.00 0.491256 0.94 0.000000 0.52 0.000014
Correlations between the exchange fluxes of amino acids, lactate and glucose and the predicted flux of selected reactions, with either the protein synthesis rate
per cell, the proliferation rate, or the proliferation rate after normalizing by cell volume. PCC, Pearson correlation coefficient; P, associated statistical significance;
PPPox, oxidative branch of the pentose phosphate pathway; PSAT, phosphoserine transaminase PC, pyruvate carboxylase; α-KG, α-ketoglutarate. Values in bold
indicate significance below P <0.05.
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correcting for cell volume
These analyses may raise the impression that the prolif-
eration rate has no impact on the metabolism of cancer
cells. However, after correcting for cell volume and con-
verting the fluxes from per cell to per-cell volume we
obtained significant correlation with the proliferation
rate. The protein synthesis rate per cell volume was
positively correlated with the proliferation rate (PCC =
0.55, P = 4 × 10-6, Figure 4). Therefore, although larger
cells tend to have a higher rate of protein synthesis per
cell (Figure 2f ), they have a lower protein synthesis rate
per cell volume (Figure 4). In contrast, smaller cells tend
to have a lower rate of protein synthesis per cell, but ahigher protein synthesis rate per cell volume due to their
relatively higher proliferation rates (Figure 4).
Theoretically, the protein synthesis rate per cell vol-
ume (fP) should be a function of the protein density
(Pd), the average molecular weight of an amino acid in
expressed proteins (waa), the basal rate of protein
turnover (kD) and the proliferation rate (μ), following
the equation:
f P ¼
Pd
waa
kD þ μð Þ ð1Þ
As discussed above, the linear scaling of the protein
content as a function of the cell volume (Figure 2d)
Figure 4 Correlation between protein synthesis and
proliferation rates after normalization by cell volume. The
protein (prot.) synthesis rate per cell volume as a function of the
proliferation rate. Each symbol represents a cell line in the NCI60
panel. The red line represents the theoretical
expectation (Equation 1).
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cell lines of Pd = 0.14 g/mL. waa can be estimated by tak-
ing into account the average amino acid composition of
expressed proteins and the amino acids molecular
weight (Additional file 1), obtaining waa = 108.89 g/mol.
Finally, the basal protein turnover is about kD = 0.01/h
[24]. Using these parameter estimates we can plot the
theoretically expected line of the protein synthesis rate
per cell volume as a function of the proliferation rate
(Equation 1). This theoretical prediction is in very good
agreement with the experimental data (Figure 4). If we
instead use kD as a free parameter and fit the theoretical
line to the experimental points in Figure 4, we obtain
kD =mean 0.015 ± SD 0.002 protein/h, which is in very
good agreement with the previous experimental report of
kD = 0.01/h [24], again supporting the validity of the
theoretical line (Equation 1).
Similarly, the exchange flux of all essential amino
acids, some non-essential amino acids (arginine, aspara-
gine, glycine, serine, tyrosine) and some of the reported
internal fluxes (PPPox, PD, PC, glutamate→ αKG, ATP
synthase) are also significantly correlated with the prolif-
eration rate when normalized by the cell volume
(Table 1). There are some notable exceptions, including
the exchange flux of the non-essential amino acids ala-
nine, aspartate, glutamate, glutamine and proline, uptake
of glucose (marginally correlated), and lactate excretion
(Table 1). Furthermore, as demonstrated previously [12]
and above (Figure 1h, Table 1), correlation betweenglycine and the proliferation rate is evident even without
normalizing by the cell size.
Large cells manifest gene expression patterns of
mesenchymal cells
To further investigate the differences between small/
highly-proliferative cells and large/slowly-proliferating
cells we analyzed previously reported basal gene expres-
sion profiles for the NCI60 panel of cell lines [17]. We
selected genes with expression manifesting high positive
correlation with the cell volumes (PCC >0.5) (Additional
file 1: Table S2). The expression of these genes clearly
increases when going from smaller to larger cell lines
(Figure 5a). Similarly, we selected genes with expression
manifesting high negative correlation with the cell vol-
umes (PCC < −0.5) (Additional file 1: Table S2). The ex-
pression of these genes clearly decreases when going
from smaller to larger cell lines (Figure 5a). The posi-
tively and negatively correlated gene lists were subjected
to GO analysis, to determine the association between
annotated pathways and cell volume. The genes with de-
creased expression in cells with larger cell volume were
enriched in GO terms related to DNA replication, cell
cycle and DNA repair (Figure 5b), corroborating the
negative correlation between cell volume and prolifera-
tion rate. In contrast, the genes with increased expres-
sion in cells with larger cell volume were enriched in
GO terms related to changes in cell morphology, traf-
ficking of proteins between cellular organelles and au-
tophagy (Figure 5c).
Cell morphology remodeling is a characteristic pheno-
type of mesenchymal cells. We hypothesized that those
genes for which expression increases/decreases with in-
creasing cell volume may manifest a similar profile dur-
ing an epithelial mesenchymal transition (EMT). To test
this hypothesis we analyzed previously reported gene ex-
pression profiles [25], characterizing the response of the
relatively small A549 cell line (indicated by the arrow in
Figure 5a) to treatment with transforming growth factor
(TGF)β, a canonical inducer of the EMT. The genes with
expression that was highly correlated with the cell vol-
ume manifested a similar pattern of expression when go-
ing from smaller to larger cell lines (Figure 5a) than
when treating the A549 cell line with TGFβ (Figure 5d).
The set of genes with expression that increased in cells
with large cell-volume exhibited increased expression
after TGFβ treatment. Similarly, the set of genes with
decreasing expression in cells with larger cell volume
manifested decreased expression after TGFβ treatment.
If larger cells are characterized by a mesenchymal
phenotype then they should express markers of mesenchy-
mal cells. To test this hypothesis we analyzed recently re-
ported reverse-phase protein array quantification of 194
proteins and phosphoproteins in the NCI60 cell lines [18].
Figure 5 Gene expression signatures of small/large cells. (a) Gene expression profile of genes with expression that increased (bottom) or
decreased (top) with increasing cell volumes (left to right) across the NCI60 cell lines. (b) Gene ontology (GO) terms enriched in genes with
expression that decreased from small to large cell lines, quantified by the enrichment significance (y-axis). (c) GO terms enriched in genes with
expression that increased from small to large cell lines. (d) Gene expression profiles of the same genes in the cell line A549 before and after
treatment with transforming growth factor (TGF)β. (e) Protein expression of vimentin and E-cadherin across the NCI60 cell lines in relation to the
cell volume (increases left to right) and the proliferation rate.
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sion and cell volume was observed for vimentin (PCC =
0.36, P = 0.0017) (Additional file 1: Table S3), a standard
marker of mesenchymal cells. This significant correl-
ation is visualized in Figure 5c, showing that the pro-
tein expression of vimentin is strongly correlated with
the cell volume, and both are inversely correlated
with the proliferation rate. In contrast, the epithelial
marker E-cadherin exhibits the second highest nega-
tive correlation between protein expression and cell
volume (PCC = −0.20, P = 0.062) (Additional file 1:Table S3), which is visually corroborated in Figure 5c.
Taken together these data indicate that the larger
cells manifest expression signatures of mesenchymal
cells.
Food and Drug Administration (FDA)-approved drugs
targeting cells with high protein synthesis or proliferation
rate
These observations indicate that there are metabolically
distinct, slowly proliferating large cancer cells with high
protein-synthesis rates per cell, and rapidly proliferating
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cell. We hypothesized that this metabolic difference may
have a significant impact on the response to targeted
therapies against cancer metabolism. To test this hy-
pothesis, we analyzed in vitro data reporting the re-
sponse of the NCI60 cell lines to 103 FDA-approved
drugs [26] (Additional file 1: Table S4). Using our previ-
ously established methodology [27], we identified drugs
with extremely low IC50 values in cells with high prolif-
eration rates relative to those with low proliferation
rates, and drugs with extremely low IC50 values in cells
with high protein-synthesis rates relative to those with
low protein-synthesis rates. In agreement with our
current knowledge, we found several antimetabolites
among the agents that are selective for highly prolifer-
ating cells, together with some toposiomerase I/II in-
hibitors and one alkylating agent (Figure 6). Among
the antimetabolites, methotrexate and 5-fluorouracil
manifested the highest selectivity (Figure 6). In con-
trast, we found that aromatase inhibitors, statins and
mTOR inhibitors are selectively inhibitory for cells
more slowly proliferating with high protein synthesis
rates per cell (Figure 6).Figure 6 Implications of cell protein synthesis and proliferation rates
in vitro sensitivity in cell lines with high protein synthesis rate per cell versu
high proliferation rate. The horizontal/vertical dashed lines represent the th
different drug classes as indicated in the legend, except for the solid squarDiscussion
Our analyses here indicate that cancer cells grown
in vitro can be roughly divided into fast proliferating
small cells (hyperplastic) with relatively low protein syn-
thesis rates per cell, and slowly proliferating large cells
(hypertrophic) with high protein synthesis rates per cell
and mesenchymal expression signatures. In turn, the as-
sessment of in vitro growth inhibition data provides can-
didate drugs for the treatment of cancer cells in the
hyperplastic and hypertrophic class. As expected, the
sensitivity to several antimetabolites correlated with
higher proliferation rates, in agreement with previous re-
ports [28,29]. In contrast, high protein synthesis rate is
associated with increased sensitivity to mTOR, aroma-
tase, and cholesterol synthesis inhibitors. mTOR is a
master regulator of protein synthesis [30] and, therefore,
the selectivity of mTOR inhibitors against cancer cells
with high protein synthesis rates is not surprising.
Statins and aromatase inhibitors target the cholesterol
and estradiol synthesis pathways, respectively, and are
not widely considered to have activity against protein
synthesis. Statins are currently under intense investiga-
tion for their cancer prevention potential [31,32]. Thefor cancer treatment. Statistical significance is shown for increased
s the statistical significance for increased sensitivity in cell lines with
reshold statistical significance of 0.05. Different symbols emphasize
es that represent other mechanisms not indicated.
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tion, indicates that statin treatment prior to cancer
diagnosis is associated with reduced rate of cancer devel-
opment [31]. The hypothesis for these observations is
that the availability of cholesterol may limit the cellular
proliferation required for cancer growth. However, the
mechanism of action behind this association and
whether it holds in vivo remains to be determined. In
addition to inhibition of cholesterol synthesis by statins,
there are reports of statin off-target effects resulting in
inhibition of protein synthesis, although a mechanistic
understanding of this inhibition is missing [33,34]. From
our analysis, we cannot exclude the possibility that lar-
ger cancer cells contain more cell membrane and thus
require more cholesterol for their proliferation. Activa-
tion of mTOR1 increases both protein synthesis and
sterol synthesis [21], indicating that these two pathways
may be co-regulated. If that were the case, then the asso-
ciation between response to statins and protein synthesis
rate could be explained by the correlation between cell
volume and protein synthesis rate and a potential correl-
ation between lipid synthesis and cell volume. Therefore,
it will be important to investigate whether lipid content
and lipid synthesis also correlate with cell volume or sur-
face area in the NCI60 panel.
In the case of aromatase inhibitors we lack a hypoth-
esis for their in vitro specificity against large cells with
high protein-synthesis rates. Aromatase inhibitors
block estrogen synthesis and they are currently used
for the treatment of estrogen receptor-positive breast
cancer [35]. Further work is required to determine the
relevance of this association in the context of other
cancer types.
It also remains to be explained why the exchange rate
of some amino acids is correlated with the proliferation
rate but not with the protein synthesis rate, glycine be-
ing the most prominent example. Experiments with 13C-
labelled glycine demonstrate the incorporation of glycine
carbons into purine nucleotides, suggesting a role in
DNA synthesis [12]. Here, we have shown that the gly-
cine exchange rate is significantly correlated with the
rate of DNA synthesis in the NCI60 panel of cell lines
grown in vitro. However, the reason why glycine is only
imported in highly proliferating cells remains unclear.
Indeed, cells could instead increase the serine import
and convert serine to glycine, as is the case in slowly
proliferating large cells. In general, the switch from one
metabolic mode to another takes place when cell metab-
olism reaches a physico-chemical constraint. A limita-
tion in the serine uptake capacity is unlikely because
among cells importing glycine there is a high variability
in the uptake of serine. On a different line of reasoning,
we note that glycine and the other amino acids showing
an atypical behavior (alanine, glutamate, glutamine, andproline) have in common their use as organic osmolytes
[36-38]. Thus, the exchange fluxes of these amino acids
may be coupled to some mechanism of cell volume
regulation. In fact, the glycine exchange rate is also
highly correlated with the volume of the NCI60 cell lines
(PCC = 0.36, P = 0.0029). While at the current stage this
is just a hypothesis, it points to a potential relationship
between cell volume regulation and molecular crowding
in cancer metabolism.
Conclusions
The NCI60 cell lines display various metabolic activ-
ities, and the type of metabolic activity that they possess
correlates with their cell volume and protein content.
Protein content, DNA content, and protein synthesis
rate per cell are proportional to the cell volume. Smaller
cells tend to have shorter doubling times. Estimated
metabolic fluxes are proportional to the protein synthe-
sis rate and, after correcting for cell volume, to the pro-
liferation rate. Genes overexpressed in smaller cells are
enriched for genes involved in cell cycle, while genes
overexpressed in large cells are enriched for genes
expressed in mesenchymal cells. The later is further
corroborated by the induction of those same genes fol-
lowing treatment with TGFβ, and the overexpression of
vimentin at the protein level in the larger cells. In
addition to cell proliferation, cell volume and/or bio-
markers of protein synthesis may predict response to
drugs targeting cancer metabolism.
Additional file
Additional file 1: Maximum likelihood method to estimate the
protein synthesis rate, personalized metabolic model of cell
metabolism, and supplementary figures and tables.
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